Autopsy report · NCT01756924

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

“This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 7 months before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Arrevus Inc.

Sponsor type

Industry

Conditions

Prosthetic Joint Infections of Hip; Prosthetic Joint Infections of Knee; Infected Spacers

Interventions

CEM-102; IV or Oral standard of care antibiotics; Rifampin

Participants

14

Sites

13

Countries

United States

Trials that died the same way

• Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
  “This study has been terminated due to meeting protocol defined futility.” (56% match in meaning)
• Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults
  “This study was terminated early due to futility.” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.